Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 5µg/20µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.

Filipino - Kiingereza - FDA (Food And Drug Administration)

astrazeneca pharmaceuticals (phils.), inc. - byetta® - solution for injection (sc) - 250 mcg/ml (10 mcg/dose)

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - byetta is indicated for treatment of type-2 diabetes mellitus in combination with:metformin;sulphonylureas;thiazolidinediones;metformin and a sulphonylurea;metformin and a thiazolidinedione;in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.

Singapoo - Kiingereza - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - exenatide - injection, solution - 250mcg

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - exenatide -

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 2mg;  ;   - injection with diluent - 2 mg - active: exenatide 2mg     excipient: 5050 dl 4ap polymer (poly(d,l-lactide-co-glycolide)) sucrose carmellose sodium dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection carmellose sodium dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with · metformin · sulphonylurea · thiazolidinedione · metformin and sulphonylurea · metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Kanada - Kiingereza - Health Canada

astrazeneca canada inc - exenatide - solution - 10mcg - exenatide 10mcg - incretin mimetics

Filipino - Kiingereza - FDA (Food And Drug Administration)

packer: enestia belgium nv; importer: astrazeneca pharmaceuticals (phils.), inc. - exenatide - solution for injection (s.c.) - 250mcg/ ml (10 mcg/ dose)

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 2 mg - injection, modified release - excipient ingredients: sucrose; polyglactin - exenatide is indicated for the treatment of type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 5.1 pharmacodynamic properties - clinical trials for available data on different combinations).

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - powder and solvent for prolonged-release suspension for inj - 2mg